Tuesday, October 13, 2020

Wall Street closes lower on vaccine delay, dampened stimulus hopes

One person in the vaccine trials gets sick so there’s a temporary halt which will likely last just a week or two. And the White House’s trimmed down stimulus package got rejected by the Democrats as being woefully inadequate for addressing the key problems. And even though both JP Morgan and Citigroup turned in Q3 reports that beat estimates, low interest rates dropped their respective share values. Add it all up and it amounted to all three indexes in the red, the Dow down 157 points. The further illogic behind today’s sell off is that, despite the two giant banks losing share value, the Q3 forecast has been changed today from a 21% loss in earnings to a 19.6% loss.  Coming later this week will be reports from giants BofA, Goldman Sachs, Wells Fargo, United Health Group, United Airlines, Morgan Stanley and Honeywell.  Volume is still below average at 8.5 billion. 

TUE  OCTOBER 13, 2020  4:22 PM 

Wall Street closes lower on vaccine delay, dampened stimulus hopes

DJ: 28,837.52  +250.62       NAS: 11,876.26  +296.32       S&P: 3,534.22  +57.09     10/12

DJ: 28,679.81  -157.71        NAS: 11,863.90  -12.36          S&P: 3,511.93  -22.29      10/13

NEW YORK (Reuters) - Wall Street lost ground on Tuesday, with halted COVID-19 vaccine trials and an elusive U.S. stimulus agreement weighing on sentiment as third quarter earnings season got underway.  While all three major stock indexes closed in the red, a gain Microsoft Corp shares helped the mitigate the tech-heavy Nasdaq’s loss.  Johnson & Johnson announced on Monday it was pausing clinical trials of a COVID-19 vaccine candidate due to an unexplained illness in a study participant. The delay weighed on the company’s shares, even after its beat-and-raise earnings report. Its shares lost 2.3%.  Late in the session, rival Eli Lilly & Co said it was also halting its coronavirus antibody trial because of safety concerns, sending its shares down 2.9%.

“We have this recent spike in coronavirus cases coinciding with big drug companies halting vaccine trials,” said Robert Pavlik, chief investment strategist at SlateStone Wealth LLC in New York. “That’s making the market nervous and in response, you’re seeing the lockdown stocks moving higher.”

Hopes for the passage of a new coronavirus relief package faded as U.S. House Speaker Nancy Pelosi rejected the $1.8 trillion coronavirus relief proposal from the White House, saying it “falls significantly short of what this pandemic and deep recession demand.”  Senate Majority Leader Mitch McConnell said the Republican-led Senate would vote on a targeted pared-down stimulus package on Monday.   “(Washington is) playing with the market’s emotions and individuals’ financial futures,” SlateStone Wealth’s Pavlik added. “As this continues, the market is looking past what they’re saying because it truly believes stimulus will come some time after the election.”

Although JPMorgan handily beat consensus profit estimates, gaining from a boom in its trading business, its peer Citigroup, while also beating expectations, was slammed by low interest rates and a slowdown in loan demand. Their shares dropped 1.6% and 4.8%, respectively.  The broader S&P Banking index lost 2.7%

Apple Inc unveiled the latest incarnation of its flagship gadget, the iPhone 12 with 5G connectivity. Its shares were down 2.7%. 

The Dow Jones Industrial Average fell 157.71 points, or 0.55%, to 28,679.81, the S&P 500 lost 22.29 points, or 0.63%, to 3,511.93 and the Nasdaq Composite dropped 12.36 points, or 0.1%, to 11,863.90.

Third-quarter reporting season has left the starting gate, and analysts now see S&P 500 earnings, in aggregate, falling by 19.6% year-on-year, according to Refinitiv.  Other earnings on tap this week include Bank of America Corp, Goldman Sachs Group Inc, Wells Fargo & Co, UnitedHealth Group and United Airlines Holdings Inc expected on Wednesday, with Morgan Stanley and Honeywell International Inc due on Thursday. 

Shares of Delta Air Lines Inc dropped 2.7% after the commercial carrier reported a 76% plunge in quarterly revenue and announced it has delayed a targeted halt to its cash bleed.  Planemaker Boeing Co reported order cancellations for its grounded 737 MAX aircraft and said deliveries were less than half the number as the same month a year ago. Its stock, was down 3.1% was the heaviest drag on the Dow.

Declining issues outnumbered advancing ones on the NYSE by a 2.00-to-1 ratio; on Nasdaq, a 1.50-to-1 ratio favored decliners.  The S&P 500 posted 39 new 52-week highs and one new low; the Nasdaq Composite recorded 123 new highs and 14 new lows.

Volume on U.S. exchanges was 8.50 billion shares, compared with the 9.72 billion average over the last 20 trading days. 


No comments:

Post a Comment